22/05/2015 13:36:44 Free Membership Login

Merck News (NYSE:MRK)

DateTimeSource
Headline
05/22/20157:12AMBWMerck Receives Positive CHMP Opinion for KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Melanoma
Opinion for KEYTRUDA Based on Efficacy and Safety Data in More than 1,500 Patients with Advanced Melanoma as Both First-Line Therapy and in those Previously Treated Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the... More...>>
05/22/20157:12AMBWMSD Receives Positive CHMP Opinion for Pembrolizumab for the Treatment of Advanced Melanoma
Opinion for Pembrolizumab Based on Efficacy and Safety Data in More than 1,500 Patients with Advanced Melanoma as First-Line Therapy and in those Previously Treated MSD, known as Merck (NYSE:MRK) in the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European... More...>>
05/20/201512:15PMTMFWhat Is the S&P 500 Index?
http://www.fool.com/investing/general/2015/05/20/what-is-the-sp-500-index.aspx?source=eptadnlnk0000002 More...>>
05/18/20159:09PMTMFThe 30 Dow Jones Stocks
http://www.fool.com/investing/general/2015/05/18/the-30-dow-jones-stocks.aspx?source=eptadnlnk0000002 More...>>
05/18/201512:18PMDJNEndo to Buy Generics Maker Par Pharma for $8 Billion -- 4th Update
By Chelsey Dulaney Endo International PLC agreed to buy Par Pharmaceutical Holdings Inc. from private-equity firm TPG for about $8 billion in cash and stock, giving Dublin-based Endo further access to profitable generic drugs. Par, which TPG took private in 2012 for about $1.9 billion, has a portfolio of nearly 100 products... More...>>
05/18/201511:05AMDJNEndo to Buy Generics Maker Par Pharma for $8 Billion -- 3rd Update
By Chelsey Dulaney Endo International PLC agreed to buy Par Pharmaceutical Holdings Inc. from private-equity firm TPG for about $8 billion in cash and stock, giving Dublin-based Endo access to profitable generic drugs. Par, which TPG took private in 2012 for about $1.9 billion, has a portfolio of nearly 100 products, including... More...>>
05/18/20159:20AMDJNEndo to Buy Par Pharma
Endo International PLC agreed to buy Par Pharmaceutical Holdings Inc. from private-equity firm TPG for about $8 billion in cash and stock, a deal that will help boost its generics business. Par, which TPG took private in 2012 for about $1.9 billion, has a portfolio of nearly 100 products, including oral solids and injectables... More...>>
05/18/20158:53AMDJNEndo to Buy Generics Maker Par Pharma for $8 Billion -- 2nd Update
By Chelsey Dulaney Endo International PLC agreed to buy Par Pharmaceutical Holdings Inc. from private-equity firm TPG for about $8 billion in cash and stock, a deal that will help boost its generics business. Par, which TPG took private in 2012 for about $1.9 billion, has a portfolio of nearly 100 products, including oral... More...>>
05/18/20158:00AMBWMerck to Present at the UBS Global Healthcare Conference
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Adam Schechter, executive vice president and president, Global Human Health, Merck, is scheduled to present at the UBS 2015 Global Healthcare Conference in New York on May 19, 2015 at 10:30 a.m. EDT. Investors, analysts, members of... More...>>
05/18/20157:44AMDJNEndo to Buy Generics Maker Par Pharma for About $8 Billion -- Update
By Chelsey Dulaney Endo International PLC has agreed to buy Par Pharmaceutical Holdings Inc. from private-equity firm TPG for about $8 billion in cash and stock, a deal that will help boost its generics business. Par, which TPG took private in 2012 for about $1.9 billion, has a portfolio of nearly 100 products, including... More...>>
05/17/20158:04PMDJNM&A Fuels Fundraising
(FROM THE WALL STREET JOURNAL 5/18/15) By Stephen Grocer Companies are turning to the capital markets at a record pace to fund acquisitions. So far this year, buyers have raised $159 billion in debt and $47.3 billion in equity to fund purchases, according to Dealogic. Both are highs for the first 4 1/2 months of the year... More...>>
05/17/20159:05AMTMF2 Stocks With Jaw-Dropping Growth Potential
http://www.fool.com/investing/general/2015/05/17/2-stocks-with-jaw-dropping-growth-potential.aspx?source=eptadnlnk0000002 More...>>
05/17/20158:04AMTMFBig Pharma Stocks: Where to Invest Your Money Now
http://www.fool.com/investing/general/2015/05/17/big-pharma-stocks-where-to-invest-your-money-now.aspx?source=eptadnlnk0000002 More...>>
05/14/20159:04AMTMFHow a Strong Dollar Affects Pharmaceutical Stocks
http://www.fool.com/investing/general/2015/05/14/how-a-strong-dollar-affects-pharmaceutical-stocks.aspx?source=eptadnlnk0000002 More...>>
05/13/20155:00PMBW2015 ASCO Annual Meeting: New Data in 10 Different Cancers from Merck’s Rapidly Expanding Immuno-Oncology Research Program ...
New Findings Show Anti-tumor Activity of KEYTRUDA in Five Additional Cancers: Colorectal, Esophageal, Ovarian, Renal Cell Carcinoma and Small-Cell Lung Cancer First-Time Presentations of DNA Mismatch Repair Deficiency Data in Colorectal and other Cancers and Nanostring RNA Data in Melanoma, Head and Neck and Gastric Cancers... More...>>
05/12/201510:26AMTMF5 Largest Markets for Pharmaceuticals
http://www.fool.com/investing/general/2015/05/12/5-largest-markets-for-pharmaceuticals.aspx?source=eptadnlnk0000002 More...>>
05/06/20159:34AMDJNGilead to Buy EpiTherapeutics for $65 Million
By Chelsey Dulaney Gilead Sciences Inc. has agreed to buy privately-held EpiTherapeutics ApS for $65 million, giving the drug maker a foothold into the field of epigenetics. Epigenetics is the study of how environmental influences alter whether particular genes are activated. Denmark-based EpiTherapeutics develops cancer... More...>>
05/04/20157:22PMDJNGeneric Drugs Grab Growing Market Share in Mexico--Update
By Amy Guthrie MEXICO CITY-Generic medicine has taken the Mexican pharmaceutical market by storm, driving sales growth in recent years, according to Mexican pharmaceutical industry group Canifarma. Generic medicine represents around 87% of human drug sales in Mexico, up from 30% in 1997, Canifarma director Rafael Gual... More...>>
05/04/20157:22PMDJNGeneric Drugs Grab Market Share in Mexico
By Amy Guthrie MEXICO CITY-Generic medicine has taken the Mexican pharmaceutical market by storm, driving sales growth in recent years, according to Mexican pharmaceutical industry group Canifarma. Generic medicine represents around 87% of human drug sales in Mexico, up from 30% in 1997, Canifarma director Rafael Gual... More...>>
05/03/20156:57AMARNBank of America Reaffirms Buy Rating for Merck & Co. (MRK)
http://tickerreport.com/banking-finance/493870/bank-of-america-reaffirms-buy-rating-for-merck-co-mrk/?utm_source=ADVFN&utm_medium=banner&utm_campaign=ADVFN More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nyse mrk150522 13:36